Quince Therapeutics, Inc. Cash Flow Conversion Efficiency
Quince Therapeutics, Inc. cash flow conversion efficiency. Based on the latest financial reports, Quince Therapeutics, Inc. (QNCX) has a cash flow conversion efficiency ratio of -0.174x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.89 Million) by net assets ($108.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Quince Therapeutics, Inc. (2017–2025)
Cash flow conversion efficiency of Quince Therapeutics, Inc. from 2017 to 2025. This chart illustrates how Quince Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Quince Therapeutics, Inc. (QNCX) share price today for real-time trading data and today's change.
Quince Therapeutics, Inc. Cash Flow Conversion Ratio Explained
Quince Therapeutics, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Quince Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Quince Therapeutics, Inc. ranked by their cash flow conversion efficiency. Also see market cap of Quince Therapeutics, Inc. for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Auctus Alternative Investments Ltd
AU:AVC
|
0.026x |
|
Xu Yuan Packaging Technology Co Ltd
TWO:8421
|
-0.026x |
|
Rockwell Medical Inc
NASDAQ:RMTI
|
0.059x |
|
PTRB
KLSE:0260
|
0.084x |
|
Comunication Weaver Co.Ltd
KQ:056360
|
-0.020x |
|
Euro Holdings Bhd
KLSE:7208
|
0.044x |
|
Shemaroo Entertainment Limited
NSE:SHEMAROO
|
0.120x |
|
North Energy ASA
OL:NORTH
|
-0.014x |
Annual Cash Flow Conversion Efficiency for Quince Therapeutics, Inc. (2017–2025)
The table below shows the annual cash flow conversion efficiency of Quince Therapeutics, Inc. from 2017 to 2025. Review Quince Therapeutics, Inc. free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-35.71 Million | $-41.42 Million | 1.160x | +209.60% |
| 2024-12-31 | $30.15 Million | $-31.90 Million | -1.058x | -392.27% |
| 2023-12-31 | $85.08 Million | $-18.29 Million | -0.215x | +50.89% |
| 2022-12-31 | $100.59 Million | $-44.04 Million | -0.438x | +17.51% |
| 2021-12-31 | $118.59 Million | $-62.93 Million | -0.531x | -79.89% |
| 2020-12-31 | $172.26 Million | $-50.82 Million | -0.295x | -2.37% |
| 2019-12-31 | $115.48 Million | $-33.28 Million | -0.288x | -75.98% |
| 2018-12-31 | $71.42 Million | $-11.70 Million | -0.164x | -133.79% |
| 2017-12-31 | $-20.28 Million | $-9.83 Million | 0.485x | -- |
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disord… Read more